These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9273472)

  • 1. [Raynaud's phenomenon: effects of terazosin].
    Paterna S; Pinto A; Arrostuto A; Cannavò MG; Di Pasquale P; Cottone C; Licata G
    Minerva Cardioangiol; 1997 May; 45(5):215-21. PubMed ID: 9273472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000956. PubMed ID: 10796398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.
    Freedman RR; Baer RP; Mayes MD
    Circulation; 1995 Sep; 92(6):1448-51. PubMed ID: 7664425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding, assessing and treating Raynaud's phenomenon.
    Boin F; Wigley FM
    Curr Opin Rheumatol; 2005 Nov; 17(6):752-60. PubMed ID: 16224254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prazosin treatment of primary Raynaud's phenomenon.
    Nielsen SL; Vitting K; Rasmussen K
    Eur J Clin Pharmacol; 1983; 24(3):421-3. PubMed ID: 6345178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study.
    Russell IJ; Lessard JA
    J Rheumatol; 1985 Feb; 12(1):94-8. PubMed ID: 3884807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Raynaud's phenomenon with alpha-lytic agents].
    Clément DL
    Rev Med Liege; 1980 Oct; 35(19):650-2. PubMed ID: 6109369
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic efficacy of alpha-adrenoceptor blockade in primary and secondary Raynaud's syndrome.
    Cleophas TJ; van Lier HJ; Faaber P; Fennis JF; van't Laar A
    Angiology; 1984 Nov; 35(11):719-23. PubMed ID: 6149709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon.
    Kahan A; Foult JM; Weber S; Amor B; Menkes CJ; Degeorges M
    Eur Heart J; 1985 Aug; 6(8):702-5. PubMed ID: 4054140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The origin of Raynaud's phenomenon.
    Nielubowicz J; Zajaç S; Szamowska R; Adamski M
    J Cardiovasc Surg (Torino); 1978; 19(6):607-14. PubMed ID: 739033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical inquiries. What is the evaluation and treatment strategy for Raynaud's phenomenon?
    Tagliarino H; Purdon M; Jamieson B; Hoekzema G
    J Fam Pract; 2005 Jun; 54(6):553-5. PubMed ID: 15939010
    [No Abstract]   [Full Text] [Related]  

  • 15. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's phenomenon. An update.
    Coffman JD
    Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New views on therapy of Raynaud's syndrome. Preliminary note].
    Giudice PA
    Minerva Med; 1980 May; 71(20):1459-60. PubMed ID: 7383404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up.
    Le Quentrec P; Lefebvre ML
    Angiology; 1991 Apr; 42(4):289-95. PubMed ID: 1673051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.